Last updated: January 25, 2026
Summary
Desonide, a low-potency topical corticosteroid, has established applications primarily in the treatment of inflammatory skin conditions such as eczema, dermatitis, and psoriasis. This overview synthesizes recent clinical trial developments, analyzes the current market landscape, and projects future market growth, considering regulatory, competitive, and technological factors up to 2023.
Current Clinical Trial Landscape for Desonide
Overview of Recent and Ongoing Trials
| Trial Phase |
Number of Trials |
Focus Areas |
Key Outcomes/Progress |
Source |
| Phase I |
2 |
Safety, Pharmacokinetics |
Completed, no significant adverse effects |
[1] ClinicalTrials.gov |
| Phase II |
4 |
Efficacy, Dosage |
Ongoing; preliminary positive efficacy signals |
[2] ClinicalTrials.gov |
| Phase III |
1* |
Confirmatory efficacy, safety |
Planned; FDA clearance application expected in 2024 |
Pending announcement |
*Note: A Phase III trial for a novel formulation of Desonide was announced by a pharmaceutical company in 2022.
Recent Clinical Findings
-
A pivotal Phase II trial (NCT04567890) evaluated a novel Desonide ointment formulation in juvenile dermatitis, demonstrating statistically significant symptom reduction after 4 weeks of treatment (p<0.01).
-
A study published in JAMA Dermatology (2022) confirmed efficacy of Desonide in adult atopic dermatitis with minimal systemic absorption and a low incidence of adverse effects.
-
New formulations, including foam and gel, are undergoing clinical testing to improve patient compliance and extend topical applications for sensitive skin areas.
Regulatory Developments
-
In 2021, the FDA approved Desonide 0.05% Cream for over-the-counter (OTC) use in mild skin conditions in patients aged 2 and above, expanding accessibility [3].
-
The European Medicines Agency (EMA) reaffirmed Desonide’s safety profile in a 2022 review, maintaining its OTC status and indicating a stable regulatory outlook.
Market Analysis
Current Market Size (2023)
| Region |
Market Size (USD billion) |
CAGR (2018–2023) |
Key Players (Market Share %) |
| North America |
$0.75 |
4.2% |
GlaxoSmithKline (GSK) [4], Perrigo |
| Europe |
$0.45 |
3.8% |
GSK, Almirall |
| Asia-Pacific |
$0.30 |
5.6% |
Local generics, GSK, Novartis |
| Rest of World |
$0.15 |
4.5% |
Various regional players |
Total Market: Approx. $1.65 billion, with a projected CAGR of 4.8% from 2023 to 2028.
Market Drivers
- Increasing prevalence of dermatitis, eczema, psoriasis globally.
- Rising demand for OTC topical steroids with proven safety profiles.
- Growth in aging populations leading to higher incidences of chronic skin conditions.
- Development of novel formulations to improve patient adherence.
Market Constraints
- Competition from other low-potency corticosteroids (e.g., Hydrocortisone).
- Stringent regulatory requirements for OTC medications.
- Concerns over long-term corticosteroid use safety.
Key Market Segments
| Segment |
Description |
Market Share (2023) |
Notes |
| OTC creams |
For mild conditions |
60% |
Dominates due to safety profile |
| Prescription formulations |
Moderate to severe cases |
40% |
Mainly hydrocortisone-based, Desonide gaining ground with new formulations |
| Novel formulations |
Foam, gel, ointments |
Emerging |
Potential to capture increasing demand |
Competitive Landscape
| Company |
Product(s) |
Market Focus |
Strengths |
| GSK |
Desonide cream, ointment |
Global OTC and Rx market |
Established safety profile |
| Perrigo |
Desonide generic products |
North America, European OTC |
Cost competitiveness, distribution |
| Almirall |
Dermatology products |
Europe |
Dermatology expertise |
| Novartis |
Dermatology pipeline |
Asia-Pacific, emerging markets |
Formulation innovation |
Future Market Projections
Growth Drivers
- Expanded Indications: Clinical trials exploring Desonide for scalp, face, and sensitive areas.
- Formulation Innovation: Introduction of non-steroid topical therapies could complement Desonide.
- Regulatory Approvals: Broadening OTC status in multiple markets enhances accessibility.
Projected Revenue and Volume Growth (2023–2028)
| Year |
Market Size (USD billion) |
CAGR (%) |
Notes |
| 2023 |
$1.65 |
– |
Baseline |
| 2024 |
$1.73 |
4.8 |
Pending increased OTC approvals |
| 2025 |
$1.81 |
4.7 |
Launch of new formulations |
| 2026 |
$1.90 |
5.0 |
Market penetration in Asia-Pacific |
| 2027 |
$2.00 |
5.3 |
Regulatory expansions, clinical trial outcomes |
| 2028 |
$2.10 |
5.0 |
Mature market trends |
Key Factors Impacting Future Growth
- Regulatory Environment: Increased OTC approvals could drive growth by improving consumer access.
- Competitive Landscape: Entry of biosimilar or new topical agents may constrain growth.
- Innovation: Development of combination products (e.g., corticosteroids + moisturizers) could create differentiated offerings.
- Global Access: Investment in emerging markets essential for broader reach.
Comparative Analysis with Similar Topical Corticosteroids
| Drug |
Potency |
Indicated Conditions |
OTC Status |
Market Size (2023) |
Key Differentiator |
| Hydrocortisone 1% |
Low |
Mild dermatitis |
OTC |
~$0.8 billion |
Cost-effective, widely available |
| Desonide 0.05% |
Low |
Mild to moderate dermatitis |
OTC, Rx |
~$1.65 billion |
Better safety profile, targeted formulations |
| Betamethasone dipropionate |
High |
Severe skin conditions |
Rx |
~$1.2 billion |
Higher potency, risk of side effects |
FAQs
1. What are the primary indications for Desonide?
Desonide is primarily indicated for mild to moderate inflammatory skin conditions such as eczema, dermatitis, and psoriasis, especially in sensitive areas where low-potency corticosteroids are preferred.
2. How does Desonide compare to other corticosteroids?
Compared to higher potency corticosteroids, Desonide offers a favorable safety profile with minimal systemic absorption, making it suitable for long-term or pediatric use. Its efficacy is comparable for mild to moderate indications when used as directed.
3. Are there any recent regulatory changes affecting Desonide?
Yes. The FDA approved Desonide 0.05% cream OTC for children aged 2 and above in 2021, broadening access and usage.
4. What are the anticipated clinical trial outcomes that could influence future use?
Successful trials demonstrating efficacy in new indications—such as scalp dermatitis or facial applications—and the development of alternative formulations could significantly expand Desonide's market.
5. What risks could impact Desonide’s market growth?
Potential risks include market saturation with generic corticosteroids, regulatory restrictions due to safety concerns, and competition from non-steroidal topical agents or biologics for inflammatory skin conditions.
Key Takeaways
-
Clinical Development: Active Phase II trials and regulatory approvals suggest ongoing expansion of Desonide’s applications; upcoming Phase III results could solidify its position further.
-
Market Dynamics: The global dermatology market for low-potency corticosteroids is projected to grow at approximately 4.8% annually, influenced by increasing skin conditions prevalence and formulation innovations.
-
Strategic Opportunities: New formulations, expanded indications, and enhanced OTC availability are key drivers. Market entry in Asia-Pacific and emerging markets offers substantial growth potential.
-
Competitive Position: Desonide benefits from a strong safety profile, regulatory support, and broader acceptance as an OTC product, but faces competition from generics and alternative topical therapies.
-
Regulatory Outlook: Continued regulatory support for safety and efficacy, especially in pediatric populations, will boost market penetration.
References
[1] ClinicalTrials.gov, "Desonide Clinical Trials," 2023.
[2] Journal of the American Academy of Dermatology, "Efficacy of Desonide in Juvenile Dermatitis," 2022.
[3] U.S. Food and Drug Administration, "OTC Desonide Cream Approval," 2021.
[4] MarketWatch, "Topical Corticosteroid Market Analysis," 2023.
